Larimar Therapeutics

Contributing Author

Recent Articles by Larimar Therapeutics

Dec-18	Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference LRMR GlobeNewswire
Nov-05	Larimar Therapeutics Reports Third Quarter 2025 Financial Results LRMR -15.26% GlobeNewswire
Sep-29	Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia LRMR -33.66% GlobeNewswire
Sep-28	Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia LRMR GlobeNewswire
Aug-14	Larimar Therapeutics Reports Second Quarter 2025 Financial Results LRMR +14.52% GlobeNewswire
Jul-31	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares LRMR GlobeNewswire
Jul-29	Larimar Therapeutics Announces Pricing of Underwritten Public Offering LRMR GlobeNewswire
Jul-29	Larimar Therapeutics Announces Proposed Underwritten Public Offering LRMR GlobeNewswire
Jul-08	Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia LRMR GlobeNewswire
Jun-23	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program LRMR -6.56% GlobeNewswire
Jun-20	Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia LRMR -5.47% GlobeNewswire